Business ExpandingArjuna Therapeutics, a Spanish company developing therapeutic medicines for intractable cancers, signs a joint research agreement with the National Cancer Center (NCC)

Nov 15, 2021

Arjuna TherapeuticsExternal site: a new window will open. was founded in 2019 and is headquartered in Galicia, Spain. In its unique platform called Therapeutic Molecular Clusters (TMCs), it is now possible to formulate new molecules with properties different from those of conventional metals while combining atoms of specific transition metals under specific conditions. The company has succeeded in creating cluster compound candidates with a new mechanism of action, and is advancing preclinical trials with the aim of developing medicines for the treatment of intractable cancers.

Establishment
2021/09
Destination
Chiba

  • Biotechnology & Lifescience
  • Spain

JETRO invited Arjuna Therapeutics to participate in the 2019 Chiba Global Business Forum (face-to-face) and arranged individual business meetings with the National Cancer Center (NCC) Hospital East and Exploratory Oncology Research & Clinical Trial Center (EPOC) (Kashiwa City, Chiba Prefecture). As a result, Arjuna Therapeutics and NCC signed a non-disclosure agreement (NDA) and a material transfer agreement (MTA). In addition, through the 2020 Chiba Global Healthcare Business Forum (online), the company was given the opportunity to pitch and meet with NCC online, which led to the conclusion of a joint research agreement in September 2021.

In this joint research, it is planned to promote translational research aimed at clarifying the mechanism of action of new cluster compound candidates created by Arjuna Therapeutics and developing cancer therapeutics under the research collaboration system between the research team led by Akihiro Ohashi, Ph.D., Head of Division of Translational Genomics at NCC EPOC, and Arjuna Therapeutics.

In addition, JETRO's Invest Japan Business Support Center (IBSC) provided information on subsidies and incentives. JETRO will continue to support the collaboration between Arjuna Therapeutics and NCC, which are challenging the unmet medical needs of intractable cancer drug discovery.


IBSCs are located in Japan's major business hubs and provide one-stop support and service to foreign firms seeking to set up or expand business in Japan. The centers, which provide free temporary office space, consultation with expert advisors and access to a wealth of business information, tailor support according to the specific needs and phase of development of each firm.

Contact Us

Investing in Japan

JETRO Worldwide

Was this information useful?

Send